Lipid nanoparticles (LNPs) containing short interfering RNA (LNP-siRNA) and optimized ionizable cationic lipids are now clinically validated systems for silencing disease-causing genes in hepatocytes following intravenous administration
Colloidal platinum nanoparticles are obtained via a surfactant-free polyol process in alkaline ethylene glycol. In this popular synthesis, ethylene glycol functions as solvent and reducing agent. The preparation procedure is known for its reproducibility to obtain 1–2 nm nanoparticles, but at the same time the controlled preparation of larger nanoparticles is challenging.